Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supraphysiologic testosterone cypionate for non-metastatic castration-resistant prostate cancer
RBR-8m3htgmNot yet recruiting
- Sponsor
- Universidade Estadual do Rio de Janeiro
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of testosterone cypionate in prostate cancer (PCa), sponsored by Universidade Estadual do Rio de Janeiro. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
testosterone cypionate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on RBR-8m3htgm.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8m3htgm.